# Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

> **NCT00514085** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 40 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** recombinant human interleukin-21
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00514085
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-13
- **Primary completion:** 2010-09-02
- **Final completion:** 2012-07-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514085, "Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00514085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*